The present study was undertaken to characterise the relationship b'/> Relationship between brain serotonin transporter binding plasma concentration and behavioural effect of selective serotonin reuptake inhibitors
首页> 美国卫生研究院文献>British Journal of Pharmacology and Chemotherapy >Relationship between brain serotonin transporter binding plasma concentration and behavioural effect of selective serotonin reuptake inhibitors
【2h】

Relationship between brain serotonin transporter binding plasma concentration and behavioural effect of selective serotonin reuptake inhibitors

机译:脑5-羟色胺转运蛋白结合血浆浓度与选择性5-羟色胺再摄取抑制剂的行为效应之间的关系

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

class="enumerated" style="list-style-type:decimal">The present study was undertaken to characterise the relationship between in vivo brain serotonin transporter (SERT) binding, plasma concentration and pharmacological effect of selective serotonin reuptake inhibitors (SSRIs) in mice. Oral administration of fluvoxamine, fluoxetine, paroxetine and sertraline at pharmacologically relevant doses exerted dose- and time-dependent binding activity of brain SERT as revealed by significant increases in KD for specific [3H]paroxetine binding, and the in vivo SERT-binding potency was in the order of paroxetine≫fluoxetine, sertraline>fluvoxamine.The time courses of brain SERT binding by SSRIs in mice were mostly in parallel to those of their plasma concentrations. Also, norfluoxetine (active metabolite) has been suggested to contribute largely to the long-lasting binding activity of brain SERT after the fluoxetine administration.Oral administration of each SSRI suppressed significantly the marble-burying behaviour with no change in locomotor activity in mice, and the extent and time course of suppression agreed well with those of brain SERT binding. Thus, the pharmacological potencies of SSRIs in the attenuation of marble-burying behaviour correlated significantly with their brain SERT binding activities.In conclusion, the present study has provided the first in vivo evidences to support that fluvoxamine, fluoxetine, paroxetine and sertraline orally administered bind to the pharmacologically relevant brain SERT in mice and that their SERT-binding characteristics is closely associated with the pharmacokinetics and inhibition of marble-burying behaviour.
机译:class =“ enumerated” style =“ list-style-type:decimal”> <!-list-behavior =枚举前缀-word = mark-type = decimal max-label-size = 0-> 进行本研究以表征小鼠体内体内脑5-羟色胺转运蛋白(SERT)结合,血浆浓度和选择性5-羟色胺再摄取抑制剂(SSRI)的药理作用之间的关系。药理学上相关剂量的氟伏沙明,氟西汀,帕罗西汀和舍曲林的口服给药具有剂量依赖性和时间依赖性的大脑SERT结合活性,这表现为特定[ 3 H]帕罗西汀结合的KD显着增加,并且体内SERT结合力的大小顺序为帕罗西汀ox氟西汀,舍曲林>氟伏沙明。 SSRIs在小鼠中对大脑SERT结合的时间进程与血浆中的浓度平行。另外,已证明去氟西汀(活性代谢产物)在氟西汀给药后对大脑SERT的持久结合活性有很大贡献。 每个SSRI的口服给药均能显着抑制大理石的埋藏行为,且无变化在小鼠的运动活动中,抑制的程度和时间过程与脑SERT结合的结果一致。因此,SSRIs减轻大理石埋藏行为的药理作用与其大脑SERT结合活性显着相关。 总而言之,本研究提供了第一个体内证据支持氟伏沙明,氟西汀,帕罗西汀和舍曲林口服给药与小鼠药理相关的大脑SERT结合,并且它们的SERT结合特性与药代动力学和抑制大理石埋藏行为密切相关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号